

APC/Fire™ 750 anti-human HLA-DR

Catalog # / 2408065 / 25 tests
Size: 2408070 / 100 tests

Clone: Tü36

Isotype: Mouse IgG2b, κ


Immunogen: Human PBL

Reactivity: Human, Non-human primate, Other

Preparation: The antibody was purified by affinity chromatography and conjugated with APC/Fire™ 750 under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human peripheral blood monocytes were stained with HLA-DR (Clone Tü36) APC/Fire™ 750 (filled histogram) or mouse IgG2b APC/Fire™ 750 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

Application Notes: Additional reported applications (of relevant formats) includes Western blotting⁴, immunoprecipitation⁴, and *in vitro* blocking⁵.

- Application References:**
1. Pawelec G, *et al.* 1985. *Hum. Immunol.* 12:165. (FC)
 2. Shaw S, *et al.* 1985. *Hum. Immunol.* 12:191. (FC)
 3. Ziegler A, *et al.* 1986. *Immunobiology.* 171:77. (FC)
 4. Cebulla CM, *et al.* 2002. *J. Immunol.* 169:167. (WB, FC, IP)
 5. Khaw LT, *et al.* 2013. *PLOS One.* 8:e69521. (Block)

Description: HLA-DR is a heterodimeric cell surface glycoprotein comprised of an α (heavy) chain and a β (light) chain. They are expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Variations in the HLA gene expression are crucial to graft survival.

- Antigen References:**
1. Thorsby E. 1974. *Transplant. Rev.* 18:51.
 2. Qvigstad E, *et al.* 1984. *Hum. Immunol.* 11:207.
 3. Servenius B, *et al.* 1984. *EMBO J.* 3:3209.
 4. Ottenhoff TH, *et al.* 1985. *Hum. Immunol.* 13:105.
 5. Strassmann G, *et al.* 1985. *Hum. Immunol.* 13:125.
 6. Trowsdale J, *et al.* 1985. *Immunol. Rev.* 85:5.